AstraZeneca delivers promising new treatment, one of the fastest-developed biologics in oncology, to address the high unmet need for third-line treatment. Enhertu (trastuzumab deruxtecan) has been...
Oncologists have characterised the genomic landscape of a rare and aggressive type of gastric cancer and identified several genes with tumour-promoting effects, paving the way for better-targeted...
An optically induced electro-kinetics (OEK) chip can separate live gastric cancer cells from ascites and peritoneal lavages, aiding in the early detection of peritoneal metastasis. Gastric cancer is...
A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a...
